NCT05970718View on ClinicalTrials.gov

A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

July 22, 2024

Study Completion Date

July 22, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

REGN7544

Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration

DRUG

Matching Placebo

Solution for single ascending IV or SC administration per the protocol

Trial Locations (1)

8011

New Zealand Clinical Research, Christchurch

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY